Baird’s Antares Pharma, Inc. ATRS Stock Holding History

Baird’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$683K	Hold	252,000	–	–	0.01%	861
2014 Q4	$648K	Buy	+252,000	New	+$566K	0.01%	864
2014 Q1	–	Sell	-194,500	Closed	-$870K	–	1178
2013 Q4	$870K	Sell	194,500 -40,200	-17%	-$164K	0.02%	656
2013 Q3	$953K	Buy	234,700 +50,700	+28%	+$221K	0.02%	601
2013 Q2	$765K	Buy	+184,000	New	+$711K	0.02%	633

Other funds holding ATRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WHI

William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Baird's ATRS Position: Q1 2015 in Review

Baird held its Antares Pharma, Inc. (ATRS) position steady in Q1 2015 at 252,000 shares worth $683K. The position accounts for 0.01% of the portfolio, ranked #861.

Baird first reported a position in ATRS in Q2 2013 and has held it in 5 quarters since. The position peaked at $953K in Q3 2013. 81 funds tracked by Wall St. Rank hold ATRS as of Q1 2015.

Baird held 252,000 shares of Antares Pharma, Inc. worth $683K as of Q1 2015.
Baird left its Antares Pharma, Inc. share count unchanged in Q1 2015.
Antares Pharma, Inc. made up 0.01% of Baird's portfolio in Q1 2015, its #861 holding.
Baird first reported a position in Antares Pharma, Inc. in Q2 2013 and has held it in 5 quarters since.
Baird's Antares Pharma, Inc. position peaked at $953K in Q3 2013.
81 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.